These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 33779349)

  • 21. Botulinum toxin-A: A novel treatment for livedoid vasculopathy.
    Crotty AM; Eubanks BN; Katana VG; Wright KT
    JAAD Case Rep; 2022 Nov; 29():27-29. PubMed ID: 36186404
    [No Abstract]   [Full Text] [Related]  

  • 22. Characteristics, risk factors and treatment reality in livedoid vasculopathy - a multicentre analysis.
    Weishaupt C; Strölin A; Kahle B; Kreuter A; Schneider SW; Gerss J; Eveslage M; Drabik A; Goerge T
    J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1784-1791. PubMed ID: 31009111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Punch grafting for the treatment of ulcerated atrophie blanche.
    Orbea Sopeña A; Conde Montero E
    Phlebology; 2023 Dec; 38(10):695-697. PubMed ID: 37624370
    [No Abstract]   [Full Text] [Related]  

  • 24. Baricitinib is potentially effective in the treatment of refractory livedoid vasculopathy.
    Han Y; Tu P
    Front Immunol; 2022; 13():1008392. PubMed ID: 36389811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ulcerative livedoid vasculopathy responding to clopidogrel.
    Kunzler E; Chong BF
    JAAD Case Rep; 2018 Mar; 4(2):203-205. PubMed ID: 29892667
    [No Abstract]   [Full Text] [Related]  

  • 26. [Vasculitis and vasculopathy].
    Marković A
    Acta Med Croatica; 2012 Oct; 66 Suppl 1():19-24. PubMed ID: 23193816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atrophie blanche: is it associated with venous disease or livedoid vasculopathy?
    Alavi A; Hafner J; Dutz JP; Mayer D; Sibbald RG; Criado PR; Senet P; Callen JP; Phillips TJ; Romanelli M; Kirsner RS
    Adv Skin Wound Care; 2014 Nov; 27(11):518-24; quiz 525-6. PubMed ID: 25325229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comprehensive review on pathogenesis, associations, clinical findings, and treatment of livedoid vasculopathy.
    Seguí M; Llamas-Velasco M
    Front Med (Lausanne); 2022; 9():993515. PubMed ID: 36569162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Home IVIG for CIDP: a focus on patient centred care.
    Katzberg HD; Rasutis V; Bril V
    Can J Neurol Sci; 2013 May; 40(3):384-8. PubMed ID: 23603176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Different dosages of intravenous immunoglobulin (IVIg) in treating immune thrombocytopenia with long-term follow-up of three years: Results of a prospective study including 167 cases.
    Zhou Z; Qiao Z; Li H; Luo N; Zhang X; Xue F; Yang R
    Autoimmunity; 2016; 49(1):50-7. PubMed ID: 26525513
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravenous immunoglobulin improves sepsis-induced coagulopathy: A retrospective, single-center observational study.
    Ishikura H; Nakamura Y; Kawano Y; Tanaka J; Mizunuma M; Ohta D; Nishida T; Murai A
    J Crit Care; 2015 Jun; 30(3):579-83. PubMed ID: 25776897
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The management of livedoid vasculopathy focused on direct oral anticoagulants (DOACs): four case reports successfully treated with rivaroxaban.
    Franco Marques G; Criado PR; Alves Batista Morita TC; Cajas García MS
    Int J Dermatol; 2018 Jun; 57(6):732-741. PubMed ID: 29663354
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous Immunoglobulin as a Treatment for Intractable Epilepsy Secondary to Focal Cortical Dysplasia: A Meta-analysis.
    Al Amrani F; Dudley R; Bello-Espinosa LE; Rosenblatt B; Srour M; Sébire G
    Pediatr Neurol; 2017 Nov; 76():79-81. PubMed ID: 28969879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methylprednisolone versus intravenous immune globulin as an initial therapy in adult primary immune thrombocytopenia.
    Kim CH; Choi YS; Moon JY; Kim DY; Lee SY; Lee HJ; Yun HJ; Kim S; Jo DY; Song IC
    Korean J Intern Med; 2019 Mar; 34(2):383-389. PubMed ID: 29172399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravenous immunoglobulin as adjuvant therapy for Wegener's granulomatosis.
    Fortin PM; Tejani AM; Bassett K; Musini VM
    Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD007057. PubMed ID: 23440811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up.
    Sami N; Letko E; Androudi S; Daoud Y; Foster CS; Ahmed AR
    Ophthalmology; 2004 Jul; 111(7):1380-2. PubMed ID: 15234140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial.
    Weishaupt C; Strölin A; Kahle B; Kreuter A; Schneider SW; Gerss J; Eveslage M; Drabik A; Goerge T
    Lancet Haematol; 2016 Feb; 3(2):e72-9. PubMed ID: 26853646
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early intravenous immunoglobulin replacement in hypogammaglobulinemic heart transplant recipients: results of a clinical trial.
    Sarmiento E; Diez P; Arraya M; Jaramillo M; Calahorra L; Fernandez-Yañez J; Palomo J; Sousa I; Hortal J; Barrio J; Alonso R; Muñoz P; Navarro J; Vicario J; Fernandez-Cruz E; Carbone J
    Transpl Infect Dis; 2016 Dec; 18(6):832-843. PubMed ID: 27639067
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-Dose Intravenous Immunoglobulin Is Effective in Painful Diabetic Polyneuropathy Resistant to Conventional Treatments. Results of a Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial.
    Jann S; Fazio R; Cocito D; Toscano A; Schenone A; Marfia GA; Antonini G; De Toni Franceschini L; Mazzeo A; Grandis M; Velardo D; Mataluni G; Peci E
    Pain Med; 2020 Mar; 21(3):576-585. PubMed ID: 31904855
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Retrospective analysis of a single-center clinical experience toward development of curative treatment of 123 pemphigus patients with a long-term follow-up: efficacy and safety of the multidrug protocol combining intravenous immunoglobulin with the cytotoxic immunosuppressor and mitochondrion-protecting drugs.
    Grando SA
    Int J Dermatol; 2019 Jan; 58(1):114-125. PubMed ID: 30047585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.